Indian Pharmaceutical Market Forecast 2016-2026

インドの医薬品市場:ジェネリック医薬品、OTC医薬品、特許薬、バイオシミラー

◆タイトル:Indian Pharmaceutical Market Forecast 2016-2026
◆商品コード:VGAIN5122116
◆調査・発行会社:visiongain
◆発行日:2015年12月
◆ページ数:194
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、インドの医薬品市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・インドのヘルスケア市場
・インドの医薬品市場
・医療のニーズ(需要)
・インドの医薬品市場:主要な治療分野
・インドの医薬品市場:主要な医薬品種類
(ジェネリック医薬品、OTC医薬品、特許薬、バイオシミラー)
・主要企業分析
・定性分析

What can be expected from the Indian Pharmaceutical market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.

Our 194-page report provides 117 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole of the Indian pharmaceutical market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications
How will submarkets perform to 2026? Our study forecasts revenues in the following Indian Pharmaceutical submarkets:
• Generic Drugs
• Over-The-Counter (OTC) Drugs
• Patented Drugs
• Biosimilars

See revenue forecasts for the leading therapeutic areas
How will leading therapeutic areas perform to 2026? Our study forecasts revenues in therapeutic areas including:
• Infectious disease drugs
• Cardiovascular disease drugs
• Gastro-intestinal drugs
• Respiratory disease
• Pain relief / analgesics
• Diabetes
• Vitamins / Minerals / Nutrients
• Dermatology
• Central Nervous System (CNS)
• Gynaecology

Leading companies and potential for market growth
Overall revenue for the Indian Pharmaceutical market will reach $36.18bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. An ageing population, increasing access to healthcare and increasing incidence of chronic diseases, especially diabetes and cardiovascular disease, will drive sales to 2026.

Our work analyses the key companies in the market. See visiongain’s analysis of leading companies, including these:
• Sun Pharmaceutical Industries Limited
• Abbott Healthcare Private Limited (Abbott India)
• Cipla Ltd.
• Cadila Healthcare Ltd.
• GlaxoSmithKline Pharmaceuticals Limited (GSK India)
• Pfizer Limited. India
• Lupin Pharmaceuticals, Inc.,

A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Historic revenue, analysis and discussion of company performance over the past 10 years
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

【レポートの目次】

1. Report Overview
1.1 The Indian Pharmaceutical Market Overview
1.2 Indian Pharmaceutical Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. Indian Healthcare: Overview
2.1 India: Demographic Indicators Overview
2.2 Indian Healthcare system: Overview
2.2.1 Rashtriya Swasthya Bima Yojana – Bringing Healthcare Coverage to India’s Poorest Workers
2.3 Analysis of India’s Healthcare Expenditure
2.4 State Bodies regulating the Indian Pharmaceutical Market
2.4.1 The Drugs and Cosmetics Act, 1940

3. Indian Pharmaceutical Market: Discussions and Predictions 2016-2026
3.1 Indian Pharmaceutical Market: The Third Biggest Market in the World by Volume, 2015
3.2 Indian Pharmaceutical Market: Overall Revenue Forecast 2016-2026

4. Medical Treatment Needs in India, 2016-2026
4.1 Disease Prevalence in India, 2016-2026
4.2 Disease Incidence in India, 2016-2026
4.3 Disease Mortality Rates in India, 2016-2026
4.3.1 Top Causes of Death in India
4.3.2 Top Causes of Death in India: Mortality Projections, 2016-2026

5. Indian Pharmaceutical Market: Leading Therapeutic Areas, 2016-2026
5.1 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Overview, 2015
5.2 Indian Pharmaceutical Market: Leading Therapeutic Areas Forecasts, 2016-2026
5.3 Infectious Disease Therapeutics: Overview, 2015
5.3.1 Infectious Disease Drugs Market: Forecast, 2016-2026
5.3.2 Diarrheal Diseases Responsible for Over Half a Million Annual Deaths, 2015
5.3.3 Lower Respiratory Tract Infections Among Leading Causes of Death in 2015
5.3.4 Tuberculosis Still Rife in India
5.3.5 Malaria, Risk and Opportunity
5.3.6 HIV in India: Growing Therapeutic Area Worth Watching
5.3.7 Drivers and Restraints for the Infectious Diseases Pharmaceutical Segment, 2015-2026
5.4 Cardiovascular Therapeutic Segment: Overview, 2015
5.4.1 Cardiovascular Disease – India’s Leading Cause of Death, 2015
5.4.2 Cardiovascular Drugs Market: Forecast, 2016-2026
5.4.3 Drivers and Restraints for the Indian Cardiovascular Drugs Market, 2015-2026
5.5 Gastro-Intestinal Therapeutic Segment: Overview, 2015
5.5.1 Gastro-Intestinal Drugs Market: Forecast, 2016-2026
5.5.2 Gastro-Intestinal Drugs in India: Challenges and Opportunities
5.5.3 Drivers and Restraints for the Gastro-Intestinal Drugs Segment, 2015
5.6 Respiratory Therapeutic Segment: Overview, 2015
5.6.1 Respiratory Disease Drugs Market: Forecast, 2016-2026
5.6.2 Drivers and Restraints for the Respiratory Diseases Segment, 2015
5.7 Pain Relief / Analgesics Therapeutic Segment: Overview, 2015
5.7.1 Pain Relief / Analgesics Drugs Market: Forecast, 2016-2026
5.7.2Drivers and Restraints for the Pain Relief / Analgesics Drugs Segment, 2015
5.8 Diabetes Therapeutic Segment: Overview, 2015
5.8.1 Diabetes Drugs Market: Forecast, 2016-2026
5.8.2 Drivers and Restraints for the Diabetes Drugs Segment, 2015
5.9 Vitamins / Minerals / Nutrients Therapeutic Segment: Overview, 2015
5.9.1 Vitamins / Minerals / Nutrients Drugs Market: Forecast, 2016-2026
5.9.2 Vitamins / Minerals / Nutrients in India: Challenges and Opportunities
5.9.3 Drivers and Restraints for the Vitamins / Minerals / Nutrients Drugs Segment, 2015
5.10 Dermatological Therapeutic Segment: Overview, 2015
5.10.1 Dermatological Drugs Market: Forecast, 2016-2026
5.10.2 Drivers and Restraints for the Dermatological Drugs Segment, 2015
5.11 Central Nervous System (CNS) Therapeutics: Overview, 2015
5.11.1 CNS Drugs Market: Forecast, 2016-2026
5.11.2 Intentional Injury Among the Top 10 Leading Causes of Death, 2015:
5.11.3 India’s Aging Population: Driver for the CNS Segment
5.11.4 Drivers and Restraints for the CNS Drugs Segment, 2015
5.12 Gynaecological Treatment Market Overview: 2015
5.12.1 Infant Mortality Still High in India
5.12.2 Indian Gynaecological Treatments Market: Forecast, 2016-2026
5.12.3 Drivers and Restraints for the Gynaecological Segment, 2015
5.13 Other Pharmaceutical Products Market Overview: 2015
5.13.1 Incidence of Cancer in India is Rising
5.13.2 Indian Other Treatments Market: Forecast, 2016-2026

6. Indian Pharmaceutical Market: Leading Drug Types, 2016-2026
6.1 Drug Types in the Indian Market: Overview, 2015
6.2 Growth Forecasts for Leading Drug Types in India, 2016-2026
6.3 Generic Drugs Dominate the Indian Pharmaceutical Market
6.3.1 Indian Generics: Overview, 2015
6.3.2 Indian Generic Drugs Market: Forecast, 2016-2026
6.3.3 Branded Generics Preferred by Many Indian Patients
6.3.4 Drivers and Restraints for the Generic Drug Market in India, 2015
6.4 Indian Over-The-Counter (OTC) Drugs Market: Overview, 2015
6.4.1 Indian OTC Market: Forecast, 2016-2026
6.4.2 Drivers and Restraints of the Indian OTC Market
6.5 Indian Patented Drugs Market: Overview, 2015
6.5.1 Indian Patented Drugs Market: Forecasts, 2016-2026
6.5.2 Drivers and Restraints for the Indian Patented Drugs Market
6.6 Indian Biosimilar Drugs, 2015
6.6.1 Indian Biosimilar Drugs Market: Forecast, 2016-2026
6.6.2 A Number of Blockbuster Drugs Coming Off-Patent Over the Next Decade
6.6.3 Drivers and Restraints of the Indian Biosimilar Drugs Market

7. The Leading Companies in the Indian Pharmaceutical Market, 2016-2026
7.1 Indian Pharmaceutical Market Overview
7.1.1 Indian Pharmaceutical Patent Law and the Effect on Big Pharmaceutical Companies
7.2 Top 50 Domestic Indian Pharmaceutical Companies, 2015
7.3 Sun Pharmaceuticals Industries Limited
7.3.1 Sun Pharma: Global Presence
7.3.1.1 Sun Pharmaceutical Sales by Region, 2015
7.3.2 Sun Pharmaceuticals Business Performance 2006-2015
7.3.3 Sun Pharmaceutical: Ranbaxy Laboratories Acquisition is the Largest Ever Deal Made by an Indian Pharmaceutical Company
7.3.3.1 Other Major M&A Activity
7.4 Abbott Healthcare Private Limited (Abbott India)
7.4.1 Abbott India: Business Performance 2006-2015
7.4.2 Abbott India: Key Brands in the Indian Pharmaceutical Market
7.4.3 Abbott India: Major and Recent M&A Activity
7.5 Cipla Ltd.
7.5.1 Cipla: Business Performance 2006-2015
7.6 Cadila Healthcare Limited
7.6.1 Cadila: Business Performance 2006-2015
7.6.2 Cadila Healthcare Revenue by Therapeutic Area 2015
7.6.3 Cadila Healthcare Revenue by Business Area 2015
7.7 GlaxoSmithKline Pharmaceuticals Limited
7.7.1 GlaxoSmithKline India: Business Performance 2006-2015
7.7.2 GlaxoSmithKline India: Revenue by Product Type, 2015
7.8 Pfizer Limited. India
7.8.1 Pfizer India: Business Performance 2006-2015
7.7.2 Pfizer India: Revenue by Product Type, 2015
7.9 Lupin
7.9.1 Lupin: Business Performance 2006-2015
7.9.2 Lupin Revenue by Therapeutic Area, 2015

8. Qualitative Analysis of the Indian Pharmaceutical Market, 2015
8.1 Indian Pharmaceutical Market: Drivers and Restraints
8.2 SWOT Analysis of the Indian Pharmaceutical Market, 2015-2026
8.3 Strengths
8.3.1 Increasing Investment in the Healthcare System
8.3.2 The Disease Burden and GDP Both Growing
8.3.3 India’s Population Set to Become the World’s Largest by 2030
8.3.4 India Popular for Pharmaceutical Outsourcing
8.4 Weaknesses
8.4.1 Stringent Pricing Regulations Hit the Indian Pharmaceutical Market
8.4.2 Poor Infrastructure Threatens to Hinder Market Potential
8.4.3 Intense Competition Driving Down Drug Prices
8.5 Opportunities
8.5.1 Global Demand for Generics Rising
8.5.2 National Rural Health Mission Driving Healthcare Access in Rural Areas
8.5.3 Significant Investment from MNCs Expected
8.5.4 Innovative Biotechnology Sector Set to Capitalise on Patent Expiries
8.6 Threats
8.6.1 Rise of Other Low-Cost Generic Exporters
8.6.2 Will the Indian Government Stick to Increasing Healthcare Expenditure?
8.6.3 Recent Warnings and Export Bans from Regulatory Bodies Hit Confidence in Indian Pharmaceuticals
8.7 Porter’s Five Forces Analysis of the Indian Pharmaceutical Market
8.7.1 Rivalry Among Competitors [High]
8.7.2 Threat of New Entrants [Low]
8.7.3 Power of Suppliers [Medium]
8.7.4 Power of Buyers [High]
8.7.5 Threat of Substitutes [Low]

9. Conclusion
9.1 The Indian Pharmaceutical Market: Growing Global Market Share
9.2 Indian Pharmaceutical Market: Chronic Diseases Becoming Increasingly Prevalent
9.3 Commercial Drivers of the Indian Pharmaceutical Market
9.4 Commercial Restraints of the Indian Pharmaceutical Market
9.5 Concluding Remarks

10. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form

List of Tables
Table 1.1 Rupee to Dollar Historical Exchange Rates 2006-2015
Table 1.2 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%) by Therapeutic Area, 2015-2026
Table 3.1 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 4.1 Leading Causes of Death in India, Proportion of Total Deaths (%) 2014
Table 4.2 Leading Types of Cancer in India by Age-Standardised Death Rate (per 100,000 People), 2014
Table 4.3 Causes of Death in India by World Ranking, 2014
Table 5.1 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2015, 2020, 2026
Table 5.2 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%) by Therapeutic Area, 2015-2026
Table 5.3 The Infectious Disease Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.4 The Indian Cardiovascular Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.5 The Indian Gastro-Intestinal Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.6 The Indian Respiratory Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.7 The Indian Pain Relief / Analgesics Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.8 The Indian Diabetes Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.9 The Indian Vitamins / Minerals / Nutrients Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.10 The Indian Dermatological Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.11 The Indian CNS Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.12 The Indian Gynaecological Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.13 The Indian Other Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 6.1 Leading Drug Types in the Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2015, 2020 and 2026
Table 6.2 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%), CAGR (%) by Drug Type, 2015-2026
Table 6.3 The Indian Generic Drug Market: Revenue ($bn), AGR (%) and CAGR (%) 2015-2026
Table 6.4 The Indian OTC Drug Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 6.5 The Indian Patented Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 6.6 Selected Biosimilar Therapeutics on the Indian Market, 2015
Table 6.7 Selected Biosimilar Therapeutics on the Indian Market, 2015 (continued)
Table 6.8 The Indian Biosimilar Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 6.9 Selected Blockbuster Biologic Patent Expiries in the US and EU, 2015-2028
Table 6.10 Selected Late-Stage Biosimilar Pipeline Products, 2015
Table 7.1 Top 50 Companies in the Indian Pharmaceutical Market: Revenue (Rs.m), Revenue ($m) and Market Share (%), 2015
Table 7.2 Sun Pharmaceuticals: Revenue Share (%) by Business Area, 2006, 2010 and 2015
Table 7.3 Sun Pharmaceuticals: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Business Area, 2015
Table 7.4 Sun Pharmaceuticals: Revenue (Rs.m), Revenue ($m), AGR (%) and CAGR (%), 2006-2015
Table 7.5 Sun Pharmaceuticals: M&A Activity, 1997-2015
Table 7.6 Abbott India: Market Share (%) and Market Rank of Key Brands
Table 7.7 Abbott India: Revenue (Rs.m), Revenue ($m), AGR (%) and CAGR (%), 2006-2015
Table 7.8 Abbott India: Key Products in India, Market Share (%) and Rank, 2015
Table 7.9 Abbott India: Key Products in India, Market Share (%) and Rank, 2015 (continued)
Table 7.10 Cipla: Total Revenue (Rs.m), Total Revenue ($m), AGR (%) and CAGR (%), 2006-2015
Table 7.11 Cipla: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Geographical Area, 2015
Table 7.12 Cadila Healthcare Ltd.: Total Revenue (Rs.m), Total Revenue ($m), AGR (%) and CAGR (%), 2006-2015
Table 7.13 Cadila Healthcare Ltd.: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Therapeutic Area, 2015
Table 7.14 Cadila Healthcare Ltd.: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Business Area, 2015
Table 7.15 GlaxoSmithKline India: Key Products in the Indian Market, 2015
Table 7.16 GlaxoSmithKline India: Key Products in the Indian Market, 2015 (continued)
Table 7.17 GlaxoSmithKline India Total Revenue (Rs.m), Total Revenue ($m), AGR (%) and CAGR (%), 2006-2015
Table 7.18 GlaxoSmithKline India: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Product Type, 2015
Table 7.19 Pfizer India: Leading Brands on the Indian Market 2015
Table 7.20 Pfizer India: Total Revenue (Rs.m), Total Revenue ($m), AGR (%) and CAGR (%), 2006-2015
Table 7.21 Pfizer India: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Product Type, 2015
Table 7.22 Lupin: Total Revenue (Rs.m), Total Revenue ($m), AGR (%) and CAGR (%), 2006-2015
Table 7.23 Lupin: Revenue Share (%) by Therapeutic Area, 2015
Table 7.24 Growth of Top Brands (%), by Therapeutic Area, 2015
Table 8.1 SWOT Analysis of the Indian Pharmaceutical Market, 2015-2026

List of Figures
Figure 1.1 Indian Pharmaceutical Market: Overview of Submarkets
Figure 2.1 Indian Population: Rural and Urban Populations (bn) and Percent of Population in Urban Areas (%), 1980-2015
Figure 2.2 Indian Population: Total Population (bn) and Annual Population Growth Rate (%), 2006-2014
Figure 2.3 Indian GDP ($bn) and GDP growth (%), 2006-2014
Figure 2.4 Access to Improved Water Sources as a Proportion of Total Population (%) and Access to Improved Sanitation as a Proportion of Total Population (%), 2006-2015
Figure 2.5 Indian GDP ($bn) and Health Expenditure as a Proportion of GDP (%), 2006-2013
Figure 2.6 Health Expenditure: Public Health expenditure as a Proportion of Total Health Expenditure (%) and Out of Pocket Expenditure as a Proportion of Private Health Expenditure 2006-2013
Figure 3.1 The Indian Pharmaceutical Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 4.1 Leading Causes of Death in India, Proportion of Total Deaths (%) 2014
Figure 5.1 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2015
Figure 5.2 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2020
Figure 5.3 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2026
Figure 5.4 The Infectious Disease Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.5 Malaria cases (m), P. falciparum cases (m) and Proportion of P. falciparum cases (%) in India, 1995-2014
Figure 5.6 Infectious Disease Market in India: Drivers and Restraints, 2015-2026
Figure 5.7 The Indian Cardiovascular Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.8 Cardiovascular Drugs Market in India: Drivers and Restraints, 2015-2026
Figure 5.9 The Indian Gastro-Intestinal Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.10 Gastro-intestinal Drugs Market in India: Drivers and Restraints, 2015-2026
Figure 5.11 The Indian Respiratory Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.12 Respiratory Drugs Market in India: Drivers and Restraints, 2015-2026
Figure 5.13 The Indian Pain Relief / Analgesics Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.14 Pain Relief / Analgesics Drugs Market in India: Drivers and Restraints, 2015-2026
Figure 5.15 The Indian Diabetes Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.16 Diabetes Drugs Market in India: Drivers and Restraints, 2015-2026
Figure 5.17 The Indian Vitamins / Minerals / Nutrients Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.18 Vitamins / Minerals / Nutrients Market in India: Drivers and Restraints, 2015-2026
Figure 5.19 The Indian Dermatological Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.20 Dermatological Drugs Market in India: Drivers and Restraints, 2015-2026
Figure 5.21 The Indian CNS Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.22 CNS Drugs Market in India: Drivers and Restraints, 2015-2026
Figure 5.23 The Indian Gynaecological Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.24 Gynaecological Drugs Market in India: Drivers and Restraints, 2015-2026
Figure 5.25 The Indian Other Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 6.1 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2015
Figure 6.2 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2020
Figure 6.3 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2026
Figure 6.4 The Indian Generic Drug Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 6.5 Generic Drug Market in India: Drivers and Restraints, 2015-2026
Figure 6.6 The Indian OTC Drug Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 6.7 OTC Drug Market in India: Drivers and Restraints, 2015-2026
Figure 6.8 The Indian Patented Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 6.9 Patented Drugs Market in India: Drivers and Restraints, 2015-2026
Figure 6.10 The Indian Biosimilar Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 6.11 Biosimilar Drug Market in India: Drivers and Restraints, 2015-2026
Figure 7.1 Sun Pharmaceuticals: Revenue Share (%) by Business Area, 2006
Figure 7.2 Sun Pharmaceuticals: Revenue Share (%) by Business Area, 2010
Figure 7.3 Sun Pharmaceuticals: Revenue Share (%) by Business Area, 2015
Figure 7.4 Sun Pharmaceuticals: Revenue ($m) and AGR (%), 2006-2015
Figure 7.5 Abbott India: Revenue ($m) and AGR (%), 2006-2015
Figure 7.6 Cipla Revenue ($m) and AGR (%), 2006-2015
Figure 7.7 Cipla: Revenue Share (%) by Geographical Area, 2015
Figure 7.8 Cadila Healthcare Ltd.: Revenue ($m) and AGR (%), 2006-2015
Figure 7.9 Cadila Healthcare Ltd.: Revenue Share (%) by Business Area, 2015
Figure 7.10 Cadila Healthcare Ltd.: Revenue Share (%) by Business Area, 2015
Figure 7.11 GlaxoSmithKline India: Revenue ($m) and AGR (%), 2006-2015
Figure 7.12 GlaxoSmithKline India: Revenue Share (%) by Product Type, 2015
Figure 7.13 Pfizer India: Revenue ($m) and AGR (%), 2006-2015
Figure 7.14 Pfizer India: Revenue Share (%) by Product Type, 2015
Figure 7.15 Lupin: Revenue ($m) and AGR (%), 2006-2015
Figure 7.16 Lupin: Revenue Share (%) by Therapeutic Area, 2015
Figure 8.1 Indian Pharmaceutical Market: Drivers and Restraints, 2015-2026
Figure 8.2 Porter’s Five Forces Analysis of the Indian Pharmaceuticals Market, 2016-2026

【レポートのキーワード】

ジェネリック医薬品、OTC医薬品、特許薬、バイオシミラー、医薬品、製薬、インド

★調査レポート[インドの医薬品市場:ジェネリック医薬品、OTC医薬品、特許薬、バイオシミラー] ( Indian Pharmaceutical Market Forecast 2016-2026 / VGAIN5122116) 販売に関する免責事項
[インドの医薬品市場:ジェネリック医薬品、OTC医薬品、特許薬、バイオシミラー] ( Indian Pharmaceutical Market Forecast 2016-2026 / VGAIN5122116) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆